We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-2.59%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
-$184M
(-7.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
48.71%
Holding
92
New
20
Increased
22
Reduced
16
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$139M |
| 2 |
Cencora
COR
|
+$76M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$69.6M |
| 4 |
Centene
CNC
|
+$65.7M |
| 5 |
McKesson
MCK
|
+$56.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$106M |
| 2 |
Humana
HUM
|
+$106M |
| 3 |
Danaher
DHR
|
+$103M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$92.3M |
| 5 |
CVS Health
CVS
|
+$91.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.69% |
| 2 | Consumer Discretionary | 4.5% |
| 3 | Real Estate | 3.92% |
| 4 | Financials | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$132B
| $212M | 9.15% |
3,584,160
+2,109,790
| +143% | +$139M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $140M | 6.04% |
1,278,228
+43,180
| +3% | +$4.48M |
|
3
Biogen
BIIB
$30.7B
| $132M | 5.7% |
466,830
+127,530
| +38% | +$41.8M |
|
|
4
Cencora
COR
$60.7B
| $107M | 4.62% |
896,680
+632,340
| +239% | +$76M |
|
5
Petco
WOOF
$794M
| $104M | 4.5% |
4,944,450
| – | – |
|
6
Natera
NTRA
$38.6B
| $100M | 4.32% |
897,646
+107,988
| +14% | +$12.4M |
|
7
Envista
NVST
$4.52B
| $94.1M | 4.06% |
2,249,972
+1,084,112
| +93% | +$45.7M |
|
|
8
McKesson
MCK
$101B
| $88.2M | 3.81% |
442,470
+281,710
| +175% | +$56.3M |
|
9
Medtronic
MDT
$110B
| $76.8M | 3.31% |
612,480
+11,760
| +2% | +$1.52M |
|
10
Boston Scientific
BSX
$68.4B
| $74.1M | 3.2% |
1,707,681
+497,111
| +41% | +$22M |
|
11
Tenet Healthcare
THC
$20.3B
| $72M | 3.11% |
1,084,240
+708,060
| +188% | +$50.2M |
|
|
NVRO
12
DELISTED
NEVRO CORP.
NVRO
| $61.6M | 2.66% |
529,230
+152,900
| +41% | +$20M |
|
|
13
Centene
CNC
$30.1B
| $61.2M | 2.64% |
+982,630
| New | +$65.7M |
|
|
14
Jazz Pharmaceuticals
JAZZ
$16.2B
| $60M | 2.59% |
+460,790
| New | +$69.6M |
|
15
Stryker
SYK
$133B
| $58.7M | 2.53% |
222,510
-50,680
| -19% | -$13.5M |
|
16
HCA Healthcare
HCA
$85.7B
| $57.6M | 2.49% |
237,360
+67,650
| +40% | +$16.5M |
|
17
BioCryst Pharmaceuticals
BCRX
$2.35B
| $55.3M | 2.39% |
3,849,470
+601,370
| +19% | +$9.48M |
|
18
LivaNova
LIVN
$4.45B
| $51.6M | 2.23% |
652,150
+527,150
| +422% | +$43.3M |
|
19
Welltower
WELL
$170B
| $50.9M | 2.2% |
617,480
+182,890
| +42% | +$15.7M |
|
20
Zimmer Biomet
ZBH
$18.4B
| $48.4M | 2.09% |
340,508
-446,752
| -57% | -$65.7M |
|
21
Universal Health Services
UHS
$9.88B
| $48.2M | 2.08% |
348,680
+23,103
| +7% | +$3.5M |
|
22
Neurocrine Biosciences
NBIX
$18.7B
| $42.8M | 1.84% |
445,739
+55,759
| +14% | +$5.27M |
|
23
Cigna
CI
$76.1B
| $42.4M | 1.83% |
+211,780
| New | +$46M |
|
24
Ventas
VTR
$47.1B
| $40M | 1.73% |
725,010
+235,370
| +48% | +$13.5M |
|
|
CANO
25
DELISTED
Cano Health, Inc.
CANO
| $34.9M | 1.51% |
+27,547
| New | +$33.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2021 Portfolio in Review
As of Q3 2021, HealthCor Management held 92 positions worth $2.32B, down 7.4% from $2.5B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
HealthCor Management withdrew a net $103M in Q3 2021, closing 19 positions and reducing 16 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $106M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Consumer Discretionary and Real Estate.
Against the trend, HealthCor Management opened a new position in Jazz Pharmaceuticals worth $60M.
- HealthCor Management's largest Q3 2021 buy was Jazz Pharmaceuticals: 460,790 shares worth $60M.
- HealthCor Management added most to Bristol-Myers Squibb in Q3 2021, an estimated $139M increase.
- HealthCor Management's biggest Q3 2021 reduction was CVS Health, cutting an estimated $91.6M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q3 2021, selling an estimated $106M.
- HealthCor Management's ten largest holdings make up 49% of its $2.32B portfolio in Q3 2021.
- HealthCor Management opened 20 new positions and closed 19 in Q3 2021.
- HealthCor Management's portfolio value fell 7.4% quarter-over-quarter to $2.32B.
Based on HealthCor Management's 13F filing for Q3 2021, filed 15 Nov 2021.